Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of the study is to monitor the safety (adverse event data) of longer-term use
of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) treatment in children with pain
associated with cancer, sickle cell disease, or severe burns and breakthrough pain (BTP) who
are receiving around the clock (ATC) opioid therapy.